HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn--a randomized controlled trial.

AbstractOBJECTIVE:
To compare the effect of two dose regimes of IVIg (0.5 g/kg vs. 1g/kg given soon after birth) on duration of phototherapy in Rh-isoimmunized neonates 32 week and above gestation.
DESIGN:
Randomized controlled trial.
SETTING:
Tertiary care hospital.
SUBJECTS:
Rh positive blood group neonates of gestation 32 weeks and above born to Rh negative mothers having positive Direct Coombs test and without any major malformation.
INTERVENTION:
Intravenous immunoglobulin (IVIg) infusion over 2 h either 0.5 g/kg (low dose group, n=19) or 1.0 g/kg (high dose group, n=19).
PRIMARY OUTCOME VARIABLE:
Duration of phototherapy.
RESULTS:
The mean duration of phototherapy was 77.3+/-57.2 h in low dose group versus 55.4+/-49 h in high dose group (mean difference=21.9; 95% CI-13.1 to 56.9). There was no difference in need for exchange transfusion (21% in both the groups) and requirement of packed red blood cells transfusion (12 transfusions in both groups). The duration of hospital stay was similar [8.4+/-6.9 and 13.6+/-14.8 days, respectively (mean difference=-5.1; 95% CI-12.8 to 2.5)]. No adverse effects of IVIg administration were noted.
CONCLUSION:
Two regimens of IVIg (0.5 g/Kg or 1 g/Kg) had comparable effect on duration of phototherapy, duration of hospital stay and exchange transfusion requirement, in Rh isoimmunized neonates of gestation 32 weeks and above.
AuthorsG Girish, D Chawla, R Agarwal, V K Paul, A K Deorari
JournalIndian pediatrics (Indian Pediatr) Vol. 45 Issue 8 Pg. 653-9 (Aug 2008) ISSN: 0019-6061 [Print] India
PMID18723908 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoglobulins, Intravenous
  • Rh-Hr Blood-Group System
Topics
  • Erythroblastosis, Fetal (drug therapy)
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Infant, Newborn
  • Rh-Hr Blood-Group System

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: